Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals held an Extraordinary General Meeting where shareholders approved several resolutions, including the ratification of prior issues and approvals for future issues of convertible notes and options. These decisions are expected to support the company’s financial strategy and enhance its capacity to advance its drug development initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focusing on improving patients’ health through pharmaceutical therapies. The company is currently developing iPPS for treating diseases with significant inflammation, such as osteoarthritis.
Average Trading Volume: 869,046
Technical Sentiment Signal: Sell
Current Market Cap: A$121.5M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.